^
Association details:
| Biomarker: | CRBN underexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | iberdomide (CC-220) (CRL4-CRBN E3 ubiquitin ligase modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)
Published date:
11/06/2019
Excerpt:
Clinical activity was observed across all dose levels with an overall response rate (ORR) of 29%, clinical benefit rate of 45%, and disease control rate of 80%....Pharmacodynamic changes in pt bone marrow by quantitative IHC scoring showed significant degradation of substrates (Ikaros, P = 0.006; Aiolos, P < 0.001; ZFP91, P < 0.001) and downregulation of c-myc (P = 0.027), including in pts refractory to POM and with low CRBN expression.
DOI:
https://doi.org/10.1182/blood-2019-124298
Trial ID:
